M1 disease detected with PSMA-PET in 46 percent of patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.

PSMA PET scans enable precise detection of prostate cancer even in its earliest stages, improving diagnostic accuracy and ...

In early trade, the ASX 200 biotech stock was up as much as 15% to $4.69. Its shares have since pulled back but remain up 3% ...

These services include specialized options tailored to various cancer types. The PSMA PET CT scan is designed for prostate ...

The centre will leverage fully automated lesion segmentation in PSMA-PET/CT imaging. Malaysia’s Sunway Medical Centre, Sunway ...

Telix Pharma’s prostate cancer PET1 imaging agent, Illuccix receives European marketing approval: Melbourne, Australia Saturday, January 18, 2025, 10:00 Hrs [IST] Telix Pharmace ...

American Oncology Institute (AOI) in collaboration with Nangia Specialty Hospital in Nagpur, has introduced the advanced Gallium generator marking a new chapter in precision medicine. It will enable ...

The firm will pay $45 million upfront for several new targeted agents that it plans to pair with isotopes to develop both ...

How do we identify non-responders to 177 Lu-PSMA using PSMA PET? There have been numerous scores/classification systems identified, including the VISION PET criteria, HIT score, PSG score, and ...

Telix’s lead imaging product, gallium-68 ( 68 Ga) gozetotide injection (also known as 68 Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug ...